Artera
Artera is a healthcare technology company providing a patient communication platform that uses AI virtual agents to streamline administrative tasks.
Secondary Market Price
How Artera Measures Up
To help you manage your Artera equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
TBD
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Artera's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Artera Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Artera's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Artera is a software-as-a-service (SaaS) company that develops digital patient communication tools for the healthcare industry. The company provides AI-powered virtual agents that use voice and text to manage patient interactions, including self-scheduling, intake, forms, and billing. Its platform is used by over 900 provider organizations, such as specialty groups, large Integrated Delivery Networks (IDNs), and federal agencies, to engage approximately 100 million patients annually. Founded in 2015 by Guillaume de Zwirek, the company has raised capital through multiple funding rounds, including a $45 million Series C round in December 2020.
The company's stated future plans involve creating a 24/7 patient experience managed by AI agents, with the goal of reducing the administrative workload for healthcare staff. Artera is focused on the development of what it terms "agentic AI" for healthcare. Recent company activities include the launch of an educational series titled 'Decoding AI Agents for Healthcare,' which focuses on security and system integration. The company's CEO has also been featured in industry publications discussing the role of AI in patient communication, and Artera has announced quarterly product webinars to provide updates on its platform and product roadmap.
- Lead Edge Capital
- Jackson Square Ventures
- Health Velocity Capital
- Heritage Medical Systems
- Summation Health Ventures
- Co-Founder, Guillaume de Zwirek
- Co-Founder, Joe Tischler
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Artera worth joining?
Evaluating an offer from a private company like Artera requires a careful assessment of its equity compensation. A platform like Prospect can help you model the potential future value of your shares to make an informed decision.
What should I do with my Artera stock?
The right strategy for your private company stock depends on your personal financial goals, risk tolerance, and tax situation. Prospect can build a personalized, multi-year plan to help you maximize the after-tax value of your equity.
Can you sell Artera stock?
Selling stock in a private company is often possible through company-approved tender offers or on secondary markets, though it is more restricted than with public stock. Prospect's tender offer tools can help you determine how much to sell and which shares are the most tax-optimal to offload.
How can I find the value of my Artera stock?
The value of private stock is not publicly listed and is typically determined by the company's 409A valuation or prices on secondary markets. Prospect uses predictive models trained on VC-grade data to help you forecast the potential future value of your shares.
What is Artera's equity worth?
A private company's equity value changes based on factors like new funding rounds, business performance, and overall market conditions. You can use Prospect to model different financial scenarios and project a range of potential outcomes for your equity's worth.
What is Artera's stock ticker symbol?
As a private company, Artera does not have a stock ticker symbol. Ticker symbols are assigned to companies only when they begin trading on a public stock exchange.
Can I buy or sell Artera stock?
Selling private stock is often possible through secondary markets or tender offers, while buying is typically limited to exercising your employee stock options. Prospect provides strategies for both exercising options and selling shares to help you make tax-optimal decisions.
What is the criteria to buy or invest in Artera stock?
For employees, the main way to acquire stock is by exercising granted options, while outside investment is generally restricted to accredited investors during funding rounds. These regulations are standard for private companies not yet listed on a public exchange.
